Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. scores highest on Nitro (56) and lowest on Price (20). Its PosiPenta is 37.02 out of 100, weaker than most similar companies.
On the Penta Grid this week, Viridian Therapeutics, Inc. is Grid #630 of 837 in the Healthcare sector in United States, and Grid #3,152 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Viridian Therapeutics, Inc. | 37.02 | 20 | 28 | 56 | 37 | 44 |
| Beam Therapeutics Inc. | 40.87 | 26 | 29 | 54 | 56 | 39 |
| Clover Health Investments, Corp. | 60.66 | 11 | 85 | 83 | 80 | 44 |
| Guardian Pharmacy Services, Inc. | 63.91 | 22 | 66 | 81 | 70 | 80 |
| TransMedics Group, Inc. | 47.64 | 48 | 51 | 40 | 53 | 46 |
| Neogen Corporation | 59.37 | 37 | 81 | 85 | 54 | 40 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -5.61 |
| P/B ratio | 3.26 |
EEarnings
| Trailing EPS | ₹-321.08 |
| Forward EPS | ₹-260.89 |
NNitro
| Price | 1802.43 |
| 52-week high | 3247.78 |
| 52-week low | 1248.34 |
| Fall from 52-week high | 44.5% |
TTorque
| Return on equity (ROE) | -65.74% |
| Debt-to-equity | 0.37 |
AAnchor
| Beta (price swings) | 1.10 |
| Market cap | ₹20,420 Cr |
| Insider holding | 0.17% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Viridian Therapeutics, Inc.'s PosiPenta score?
Viridian Therapeutics, Inc.'s PosiPenta is 37.02 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does Viridian Therapeutics, Inc. stand on the Penta Grid?
On the Penta Grid this week, Viridian Therapeutics, Inc. is Grid #630 of 837 in the Healthcare sector in United States, and Grid #3,152 of 4,000 in United States.
Which PosiPenta pillar is strongest for Viridian Therapeutics, Inc.?
Nitro (momentum), with a score of 56 out of 100: around the middle of similar companies.
Which PosiPenta pillar is weakest for Viridian Therapeutics, Inc.?
Price (valuation), with a score of 20 out of 100: weaker than most similar companies.
Has Viridian Therapeutics, Inc.'s PosiPenta changed since last week?
Yes, it rose 3.86 points, from 33.16 to 37.02.
PositoAI is for research and education only and is not investment advice.